Cover Image

Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?

The treatment of patients with glioblastoma remains a challenge. Several large clinical trials of the last decades have failed and had—in retrospect—been built on over interpreted uncontrolled or inadequately controlled phase II trials or retrospective case series. Despite this disappointing experie...

Full description

Saved in:
Bibliographic Details
Main Authors: Tabatabai, Ghazaleh (Author) , Platten, Michael (Author) , Preusser, Matthias (Author) , Weller, Michael (Author) , Wick, Wolfgang (Author) , van den Bent, Martin (Author)
Format: Article (Journal) Editorial
Language:English
Published: January 2025
In: Neuro-Oncology
Year: 2025, Volume: 27, Issue: 1, Pages: 302-305
ISSN:1523-5866
DOI:10.1093/neuonc/noae225
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1093/neuonc/noae225
Verlag, kostenfrei, Volltext: https://academic.oup.com/neuro-oncology/article/27/1/302/7904860
Get full text
Author Notes:Ghazaleh Tabatabai, Michael Platten, Matthias Preusser, Michael Weller, Wolfgang Wick, Martin van den Bent
Description
Summary:The treatment of patients with glioblastoma remains a challenge. Several large clinical trials of the last decades have failed and had—in retrospect—been built on over interpreted uncontrolled or inadequately controlled phase II trials or retrospective case series. Despite this disappointing experience and critical reviews, the temptation to demonstrate the value of novel experimental treatments without randomized trials using external control data and then to report a positive outcome compared to those “historical” or “external” controls remains. Recently reported “real-world observation” of glioblastoma patients treated with a personalized peptide vaccine led by a German for-profit center1 is yet another example of such an attempt. As we anticipate misunderstandings and erroneous conclusions from this publication, we reviewed the data and the conclusions presented from a clinical and translational science perspective.
Item Description:Online veröffentlicht: 19. November 2024
Gesehen am 14.04.2025
Physical Description:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noae225

Similar Items